NCT00849381View on ClinicalTrials.gov

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand

PHASE3CompletedINTERVENTIONAL
Enrollment

1,239

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Infections, Papillomavirus
Interventions
BIOLOGICAL

GSK580299, GSK Biological's HPV vaccine

All subjects will receive 3 doses administered as an intramuscular injection, according to a 0, 1, 6-month schedule.

Trial Locations (9)

100

GSK Investigational Site, Taipei

112

GSK Investigational Site, Taipei

114

GSK Investigational Site, Taipei

10330

GSK Investigational Site, Bangkok

10400

GSK Investigational Site, Bangkok

10700

GSK Investigational Site, Bangkok

90035-003

GSK Investigational Site, Porto Alegre

13083-970

GSK Investigational Site, Campinas

80060-150

GSK Investigational Site, Curitiba

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00849381 - Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand | Biotech Hunter | Biotech Hunter